[PDF] Top 20 Avances en los estudios sobre la interacción Musa spp.-Mycosphaerella fijiensis Morelet

... after treatment was ...overall survival (OS), progression-free survival (PFS) and time to progression (TTP) of the treated patients were ...the patients was discontinued from ...were ... See full document

... significant survival benefit in older NDMM patients on protease inhibitor therapy in this study, which was inconsistent with other investigators ...with bortezomib was not consistent with the ... See full document

... related factors of the inductive therapy combined with autologous hematopoietic stem cell transplantation therapy as well as the initial overall scheme treatment of post- transplantation consolidation and ... See full document

... his study compared in a univariate and multivariate analyses these three prognostic ...This study demonstrates that the COREP score can identify patients who may quickly experience systemic ... See full document

... plus dexamethasone (Len+Dex) with placebo plus dexamethasone in patients with re- lapsed or refractory MM (, ...oral dexamethasone  mg was administered on days -, -, - of each ... See full document

... regimen. A larger SUCRA score indicated better efficacy in terms of a specific outcome measure. For the final ranking regarding the overall efficacy, an arithmetic weighted average of SUCRA scores across NRR, PFS, ... See full document

... if patients had experienced a myeloma-defining event, or “CRAB” criteria were ...that patients with MGUS or SMM be only treated within the context of a well-designed clinical ...immediate ... See full document

... Chi-squared test, t-test, and Fisher’s exact test were used to compare demographic characteristics. Curves for OS and PFS were plotted according to the Kaplan–Meier method and were compared to those of patients ... See full document

... Multiple myeloma (MM) is a B cell malignancy characterized by excess monotypic plasma cells in the BM in association with monoclonal protein in serum and/or urine, decreased normal immunoglobulin (Ig) ... See full document

... MM patients with median 5 prior lines of therapy (range: 1 – ...The patients received selinexor at two different dose levels, once or twice weekly, ixazomib on days 1,8,15 and dexamethasone on the ... See full document

... relapsed patients with MM, which might bring in bias of the ...three-drug regimen and four-drug regi- men, though VTD presentes a similar CR and ORR with VTDC and hence is consi- dered as effective as VTDC ... See full document

... This study was approved by the Institutional Review Board of Taipei Veterans General ...consecutive patients diagnosed with multiple myeloma in Taipei Veterans General Hospital were ... See full document

... the treatment of symptomatic MM, particularly with the advent of proteasome inhibitors (such as bortezomib) and immunomodulatory agents (such as lenalidomide), which have become the pillars of frontline ... See full document

... Surgical treatment for metastatic spinal disease always strive for the maximum palliative effect, including relieving pain and restoring the function and stability of the spine, with a minimum of op- erative ... See full document

... our patients, but CRBN gene muta- tions were found in only three ...One study identi fi ed a CRBN truncating mutation and a CRBN point mutation in 1 of 30 MM patients, and two CRBN SNPs in 24 ... See full document

... the study by Rajkumar SV et ...Len-Dex regimen was 6 % and 12 % respectively. In the study conducted by Segeren CM et ...VAD regimen is about 22% 9 ...VAD regimen observed by ... See full document

... allograft patients suggests that this disease is caused by monoclonal im- munoglobulin or other pathogenic factors circulating in the serum ...with multiple myeloma (MM) have been re- ported ... See full document

... recently, treatment for multiple myeloma consisted of either single agent or combination regimens of chemotherapy drugs such as melphalan, doxorubicin and vincristine, and the ... See full document

... the treatment of ...in myeloma cell lines at concentrations low enough for safe use in ...in myeloma cell lines are markedly enhanced by the addition of ascorbic acid, as reported both in vitro and ... See full document

... our study, compared with data from patients of western origin reported in the TARGET study, revealed a higher incidence of hand-foot skin reaction ...in Chinese patients with advanced ... See full document